Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor
Edgar G. Fischer, … , Barbara M. Mueller, Wolfram Ruf
Edgar G. Fischer, … , Barbara M. Mueller, Wolfram Ruf
Published November 1, 1999
Citation Information: J Clin Invest. 1999;104(9):1213-1221. https://doi.org/10.1172/JCI7750.
View: Text | PDF
Article

Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor

  • Text
  • PDF
Abstract

Tissue factor (TF), the cell-surface receptor for coagulation factor VIIa, supports metastasis. Equally important for this process are (a) interactions of the TF cytoplasmic domain, which binds the mobility-enhancing actin-binding protein 280, and (b) the formation of a proteolytically active TF-VIIa complex on the tumor cell surface. In primary bladder carcinoma cells, we find that this complex localizes to the invasive edge, in proximity to tumor-infiltrating vessels that stain intensely for TF pathway inhibitor (TFPI-1), the major inhibitor of the protease activity of the complex. In culture, binding of VIIa to TF-expressing tumor cells is sufficient to allow cell adhesion, migration, and intracellular signaling on immobilized TFPI-1. Immobilized heparin, a mimic for extracellular matrix–associated proteoglycans, binds physiological concentrations of TFPI-1 in a conformation that supports TF-VIIa–dependent cell adhesion. Consistent with a functional role of TFPI-1 in complex extracellular matrices, we show that TF cooperates with integrin-mediated adhesion and migration on composite matrices that contain ligands for both integrins and the TF-VIIa complex. This study thus provides evidence for a novel mechanism of protease-supported migration that is independent of proteolytic matrix degradation but rather involves protease-dependent bridging of TF’s extracellular domain to an ECM-associated inhibitor.

Authors

Edgar G. Fischer, Matthias Riewald, Hui-Yu Huang, Yohei Miyagi, Yoshinobu Kubota, Barbara M. Mueller, Wolfram Ruf

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Potency of immobilized TFPI-1 to promote TF-VIIa–mediated cell adhesion....
Potency of immobilized TFPI-1 to promote TF-VIIa–mediated cell adhesion. Plates were coated with the indicated concentrations of recombinant TFPI-1 or fibronectin. Adhesion of J82 cells was analyzed in the presence of 5 U/mL heparin; VIIa (10 nM) was added to cells for TFPI adhesion. Inset: Competition of solution-phase TFPI-1. Wells were coated with 0.5 μg/mL TFPI-1. TFPI-1 at the indicated concentrations was added with the cells in the presence of 10 nM VIIa or both VIIa and factor Xa (Xa).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts